ArticleEClinicalMedicine2023
Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial.
Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Microbial volatile organic compounds and olfactory receptors in wound malodor.Frontiers in cellular and infection microbiology · 2026Pooled it
- The dual role of the microbiome in chronic wound management.Cell communication and signaling : CCS · 2026Review
- Ultradeformable Vesicles for Wound Healing: Ethosomes, Transferosomes, and Transethosomes in Topical Drug Delivery.Pharmaceutics · 2026Review
- Harnessing Microbiome-Mediated and Macrophage-Driven Mechanisms for Oral Wound Healing.Microorganisms · 2026Review
- Microbial allies in skin trauma recovery: from immune modulation to engineered probiotic therapeutics.Burns & trauma · 2026Review
- The human skin microbiome: from metagenomes to therapeutics.Nature reviews. Microbiology · 2025Review
- Living probiotics-loaded wound matrices prepared by microchip electrospinning.Materials today. Bio · 2025Article
- An in vitro neurobacterial interface reveals direct modulation of neuronal function by gut bacteria.Scientific reports · 2025Article
- In Vitro Elimination of Highly Multidrug-Resistant Bacteria by the Lactic Acid Bacterial Drug Candidate ILP100.Infectious diseases and therapy · 2025Article
- Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer.Biomolecules · 2025Article
- Skin microbiome and dermatologic disorders.The Journal of clinical investigation · 2025Review
- Gut microbiota-derived metabolites in keloid and hypertrophic scarring.Frontiers in microbiology · 2025Review
- Chemokines in the resolution of inflammation: key players and targets for therapeutic modulation.Frontiers in immunology · 2025Review
- Advances in Microbiome-Based Therapeutics for Dermatological Disorders: Current Insights and Future Directions.Experimental dermatology · 2024Review
- Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions.Microbial biotechnology · 2024Review
- Delivery of a sebum modulator by an engineered skin microbe in mice.Nature biotechnology · 2024Article
- Macrophages behave like mural cells to promote healing of ischemic muscle injury.Nature cardiovascular research · 2024Article
- Tetrahedral framework nucleic acids for improving wound healing.Journal of nanobiotechnology · 2024Review
- Recent advances in single-cell engineered live biotherapeutic products research for skin repair and disease treatment.NPJ biofilms and microbiomes · 2023Review
- Antimicrobial activity of dietary supplements based on bacterial lysate ofFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Impaired wound healing is a growing medical problem and very few approved drugs with documented clinical efficacy are available. CXCL12-expressing lactic acid bacteria, Methods: SITU-SAFE is an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial (EudraCT 2019-000680-24) consisting of a single (SAD) and a multiple ascending dose (MAD) part of three dose cohorts each. The study was performed at the Phase 1 Unit, Uppsala University Hospital, Uppsala, Sweden. Data in this article were collected between Sep 20th, 2019 and Oct 20th 2021. In total 240 wounds were induced on the upper arms in 36 healthy volunteers. SAD: 12 participants, 4 wounds (2/arm), MAD: 24 participants, 8 wounds (4/arm). Wounds in each participant were randomised to treatment with placebo/saline or ILP100-Topical. Findings: In all individuals and doses, ILP100-Topical was safe and well-tolerated with no systemic exposure. A combined cohort analysis showed a significantly larger proportion of healed wounds (p = 0.020) on Day 32 by multi-dosing of ILP100-Topical when compared to saline/placebo (76% (73/96) and 59% (57/96) healed wounds, respectively). In addition, time to first registered healing was shortened by 6 days on average, and by 10 days at highest dose. ILP100-Topical increased the density of CXCL12 Interpretation: The favourable safety profile and observed effects on wound healing support continued clinical development of ILP100-Topical for the treatment of complicated wounds in patients. Funding: Ilya Pharma AB (Sponsor), H2020 SME Instrument Phase II (#804438), Knut and Alice Wallenberg foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.